NPORT-EX 2 b_021nport053123.htm QUARTERLY PORTFOLIO HOLDINGS
Putnam Global Health Care Fund
The fund's portfolio
5/31/23 (Unaudited)


COMMON STOCKS (95.1%)(a)
        Shares Value
Biotechnology (14.8%)
AbbVie, Inc. 236,800 $32,668,928
Alkermes PLC(NON) 1,970,846 57,016,575
Argenx SE (Netherlands)(NON) 21,781 8,477,979
Ascendis Pharma A/S ADR (Denmark)(NON)(S) 646,181 56,198,362
Biogen, Inc.(NON) 59,400 17,606,754
BioMarin Pharmaceutical, Inc.(NON) 122,500 10,650,150
ImmunoGen, Inc.(NON) 329,676 4,496,781
Regeneron Pharmaceuticals, Inc.(NON) 32,400 23,832,144
Rocket Pharmaceuticals, Inc.(NON) 479,400 10,033,842
Sarepta Therapeutics, Inc.(NON) 31,200 3,856,320
224,837,835
Consumer staples distribution and retail (0.4%)
Walgreens Boots Alliance, Inc. 213,800 6,493,106
6,493,106
Health care equipment and supplies (13.7%)
Boston Scientific Corp.(NON) 990,500 50,990,940
Dexcom, Inc.(NON) 480,800 56,378,608
Intuitive Surgical, Inc.(NON) 266,200 81,947,008
Lantheus Holdings, Inc.(NON) 172,400 14,928,116
Terumo Corp. (Japan) 141,900 4,312,790
208,557,462
Health care providers and services (18.5%)
Cigna Corp. 122,800 30,381,948
Humana, Inc. 72,800 36,536,136
McKesson Corp. 95,200 37,207,968
Option Care Health, Inc.(NON) 1,445,900 39,834,545
UnitedHealth Group, Inc. 281,200 137,011,888
280,972,485
Life sciences tools and services (8.7%)
Danaher Corp. 119,200 27,370,704
Illumina, Inc.(NON) 102,600 20,176,290
IQVIA Holdings, Inc.(NON) 110,300 21,719,173
Thermo Fisher Scientific, Inc. 125,500 63,811,730
133,077,897
Pharmaceuticals (39.0%)
4Front Ventures Corp.(NON)(AFF) 49,896,829 8,232,977
AstraZeneca PLC (United Kingdom) 665,729 96,701,976
Curaleaf Holdings, Inc.(NON)(S) 583,058 1,667,546
Daiichi Sankyo Co., Ltd. (Japan) 541,100 17,521,753
Eisai Co., Ltd. (Japan) 109,300 6,941,444
Eli Lilly and Co. 219,700 94,352,362
Green Thumb Industries, Inc.(NON)(S) 284,400 2,175,660
Innoviva, Inc.(NON)(AFF) 5,214,419 70,342,512
Johnson & Johnson 321,674 49,878,770
Merck & Co., Inc. 619,738 68,425,273
Novo Nordisk A/S Class B (Denmark) 421,305 67,697,579
Sanofi (France)(NON) 800,913 81,353,192
Takeda Pharmaceutical Co., Ltd. (Japan) 603,800 19,158,885
TerrAscend Corp. (Canada)(NON) 5,090,605 8,501,343
592,951,272
Total common stocks (cost $1,062,769,415) $1,446,890,057








U.S. TREASURY OBLIGATIONS (0.2%)(a)
        Principal amount Value
U.S. Treasury Notes
1.75%, 11/15/29(i) $416,000 $369,986
1.625%, 5/15/31(i) 1,108,000 956,282
1.625%, 8/15/29(i) 173,000 153,525
1.625%, 2/15/26(i) 1,004,000 945,055
0.75%, 4/30/26(i) 19,000 17,269
0.375%, 1/31/26(i) 33,000 29,954
Total U.S. treasury obligations (cost $2,472,071) $2,472,071








SHORT-TERM INVESTMENTS (8.2%)(a)
        Principal amount/shares Value
Putnam Cash Collateral Pool, LLC 5.29%(AFF) Shares 51,446,550 $51,446,550
Putnam Short Term Investment Fund Class P 5.21%(AFF) Shares 70,252,431 70,252,431
State Street Institutional U.S. Government Money Market Fund, Premier Class 5.02%(P) Shares 980,000 980,000
U.S. Treasury Bills 4.975%, 11/2/23(SEGSF) $1,432,000 1,400,154
U.S. Treasury Bills 5.453%, 10/26/23(SEGSF) 800,000 782,805
Total short-term investments (cost $124,864,510) $124,861,940
TOTAL INVESTMENTS
Total investments (cost $1,190,105,996) $1,574,224,068








FORWARD CURRENCY CONTRACTS at 5/31/23 (aggregate face value $905,222,817) (Unaudited)
  Counterparty Currency Contract type* Delivery
date		 Value Aggregate face value Unrealized
appreciation/
(depreciation)
Bank of America N.A.
Australian Dollar Buy 7/19/23 $46,197 $48,059 $(1,862)
British Pound Buy 6/21/23 4,589,038 4,560,824 28,214
British Pound Sell 6/21/23 4,589,038 4,599,022 9,984
British Pound Sell 9/20/23 4,594,762 4,566,023 (28,739)
Danish Krone Buy 6/21/23 20,948,398 21,467,694 (519,296)
Danish Krone Sell 6/21/23 20,948,398 20,991,425 43,027
Euro Buy 6/21/23 2,574,905 2,620,363 (45,458)
Euro Sell 6/21/23 2,574,905 2,597,577 22,672
Swiss Franc Buy 6/21/23 44,150,526 43,069,436 1,081,090
Swiss Franc Sell 6/21/23 44,150,526 44,403,484 252,958
Swiss Franc Buy 9/20/23 44,593,530 44,858,232 (264,702)
Barclays Bank PLC
British Pound Buy 6/21/23 3,865,639 3,832,456 33,183
British Pound Sell 6/21/23 3,865,639 3,860,956 (4,683)
Euro Buy 6/21/23 4,959,231 4,945,461 13,770
Euro Sell 6/21/23 4,959,231 5,002,879 43,648
Citibank, N.A.
Danish Krone Buy 6/21/23 38,190,679 38,367,329 (176,650)
Danish Krone Sell 6/21/23 38,190,679 39,133,163 942,484
Danish Krone Sell 9/20/23 32,481,515 32,608,356 126,841
Goldman Sachs International
British Pound Buy 6/21/23 5,633,381 5,601,960 31,421
British Pound Sell 6/21/23 5,633,381 5,420,594 (212,787)
British Pound Sell 9/20/23 5,640,408 5,608,185 (32,223)
Canadian Dollar Sell 7/19/23 1,794,424 1,814,551 20,127
Japanese Yen Buy 8/16/23 17,272,808 17,576,481 (303,673)
HSBC Bank USA, National Association
British Pound Buy 6/21/23 7,771,349 7,725,884 45,465
British Pound Sell 6/21/23 7,771,349 7,478,585 (292,764)
British Pound Sell 9/20/23 7,543,304 7,497,062 (46,242)
Canadian Dollar Sell 7/19/23 2,599,157 2,628,286 29,129
Danish Krone Buy 6/21/23 10,508,607 10,546,591 (37,984)
Danish Krone Sell 6/21/23 10,508,607 10,502,054 (6,553)
Danish Krone Sell 9/20/23 10,570,501 10,609,028 38,527
Euro Buy 6/21/23 10,813,681 10,909,349 (95,668)
Euro Sell 6/21/23 10,813,681 10,994,263 180,582
Swiss Franc Buy 6/21/23 50,297,934 49,563,369 734,565
Swiss Franc Sell 6/21/23 50,297,934 50,616,837 318,903
Swiss Franc Buy 9/20/23 46,151,777 46,425,209 (273,432)
JPMorgan Chase Bank N.A.
British Pound Buy 6/21/23 6,136,264 6,099,681 36,583
British Pound Sell 6/21/23 6,136,264 5,905,458 (230,806)
British Pound Sell 9/20/23 3,248,082 3,223,017 (25,065)
Euro Buy 6/21/23 1,983,264 1,999,741 (16,477)
Euro Sell 6/21/23 1,983,264 1,992,255 8,991
Euro Sell 9/20/23 1,993,114 2,009,543 16,429
Morgan Stanley & Co. International PLC
Australian Dollar Buy 7/19/23 2,559,236 2,661,437 (102,201)
British Pound Buy 6/21/23 6,677,974 6,637,850 40,124
British Pound Sell 6/21/23 6,677,974 6,424,780 (253,194)
British Pound Sell 9/20/23 6,686,303 6,645,126 (41,177)
Euro Buy 6/21/23 11,566,902 11,666,596 (99,694)
Euro Sell 6/21/23 11,566,902 11,693,887 126,985
Euro Sell 9/20/23 3,164,421 3,190,220 25,799
Swiss Franc Buy 6/21/23 10,093,237 10,319,983 (226,746)
Swiss Franc Sell 6/21/23 10,093,237 10,151,470 58,233
Swiss Franc Buy 9/20/23 10,194,512 10,255,255 (60,743)
NatWest Markets PLC
Australian Dollar Buy 7/19/23 22,999,304 23,916,636 (917,332)
British Pound Buy 6/21/23 4,651,136 4,509,436 141,700
British Pound Sell 6/21/23 4,651,136 4,645,526 (5,610)
Danish Krone Buy 6/21/23 6,429,922 6,480,977 (51,055)
Danish Krone Sell 6/21/23 6,429,922 6,426,097 (3,825)
Danish Krone Sell 9/20/23 3,267,423 3,280,173 12,750
State Street Bank and Trust Co.
British Pound Buy 6/21/23 10,765,125 10,544,514 220,611
British Pound Sell 6/21/23 10,765,125 10,578,735 (186,390)
Canadian Dollar Sell 7/19/23 1,306,068 1,320,589 14,521
Euro Buy 6/21/23 4,068,720 4,164,633 (95,913)
Euro Sell 6/21/23 4,068,720 4,104,511 35,791
Israeli Shekel Buy 7/19/23 2,197,869 2,299,633 (101,764)
Swiss Franc Buy 6/21/23 19,306,811 18,825,039 481,772
Swiss Franc Sell 6/21/23 19,306,811 19,421,297 114,486
Swiss Franc Buy 9/20/23 19,500,535 19,620,148 (119,613)
Toronto-Dominion Bank
Swiss Franc Buy 6/21/23 4,604,641 4,663,040 (58,399)
Swiss Franc Sell 6/21/23 4,604,641 4,645,906 41,265
UBS AG
Danish Krone Buy 6/21/23 12,694,817 12,739,965 (45,148)
Danish Krone Sell 6/21/23 12,694,817 12,687,001 (7,816)
Danish Krone Sell 9/20/23 12,769,589 12,816,685 47,096
Japanese Yen Buy 8/16/23 960,870 977,703 (16,833)
Swiss Franc Buy 6/21/23 1,423,923 1,388,562 35,361
Swiss Franc Sell 6/21/23 1,423,923 1,432,096 8,173
Swiss Franc Buy 9/20/23 1,438,211 1,446,673 (8,462)
WestPac Banking Corp.
British Pound Buy 6/21/23 14,299,988 14,283,152 16,836
British Pound Sell 6/21/23 14,299,988 13,760,381 (539,607)
Euro Buy 6/21/23 157,728 157,267 461
Euro Sell 6/21/23 157,728 159,116 1,388
Unrealized appreciation 5,481,945
Unrealized (depreciation) (5,556,586)
Total $(74,641)
* The exchange currency for all contracts listed is the United States Dollar.












Key to holding's abbreviations
ADR American Depository Receipts: Represents ownership of foreign securities on deposit with a custodian bank.
Notes to the fund's portfolio
Unless noted otherwise, the notes to the fund's portfolio are for the close of the fund's reporting period, which ran from September 1, 2022 through May 31, 2023 (the reporting period). Within the following notes to the portfolio, references to "Putnam Management" represent Putnam Investment Management, LLC, the fund's manager, an indirect wholly-owned subsidiary of Putnam Investments, LLC, references to "ASC 820" represent Accounting Standards Codification 820 Fair Value Measurements and Disclosures and references to "OTC", if any, represent over-the-counter.
(a) Percentages indicated are based on net assets of $1,521,858,731.
(NON) This security is non-income-producing.
(AFF) Affiliated company. For investments in Putnam Cash Collateral Pool, LLC and Putnam Short Term Investment Fund, the rate quoted in the security description is the annualized 7-day yield of the fund at the close of the reporting period. Transactions during the period with any company which is under common ownership or control were as follows:
Name of affiliate Fair value as of 8/31/22 Purchase Cost Sale Proceeds Investment Income Realized gain (loss) unrealized appreciation (depreciation) outstanding as of 5/31/23 Fair value as of 5/31/23
Short-term investments
Putnam Cash Collateral Pool, LLC*# $84,524,981 $278,943,369 $312,021,800 $2,639,322 $— $— 51,446,550 $51,446,550
Putnam Short Term Investment Fund** 45,137,290 289,611,020 264,495,879 1,660,219 — — 70,252,431 70,252,431
Total Short-term investments 129,662,271 568,554,389 576,517,679 4,299,541 — — 121,698,981
Common stocks***
Health care
4Front Ventures Corp. 27,882,348 — — — — (19,649,371) 49,896,829 8,232,977
Innoviva, Inc. 52,326,976 15,879,533 1,450,771 — (485,764) 4,072,538 5,214,419 70,342,512
Total Common stocks 80,209,324 15,879,533 1,450,771 — (485,764) (15,576,833) 78,575,489
Totals $209,871,595 $584,433,922 $577,968,450 $4,299,541 $(485,764) $(15,576,833) $200,274,470
* The fund may lend securities, through its agent, to qualified borrowers in order to earn additional income. The loans are collateralized by cash in an amount at least equal to the fair value of the securities loaned. The fair value of securities loaned is determined daily and any additional required collateral is allocated to the fund on the next business day. The remaining maturities of the securities lending transactions are considered overnight and continuous. The risk of borrower default will be borne by the fund’s agent; the fund will bear the risk of loss with respect to the investment of the cash collateral. The fund receives cash collateral, which is invested in Putnam Cash Collateral Pool, LLC, a limited liability company managed by an affiliate of Putnam Management. Investments in Putnam Cash Collateral Pool, LLC are valued at its closing net asset value each business day. There are no management fees charged to Putnam Cash Collateral Pool, LLC and there were no realized or unrealized gains or losses during the period.
# At the close of the reporting period, the fund received cash collateral of $51,446,550 for securities loaned. The rate quoted in the security description is the annualized 7-day yield at the close of the reporting period. At the close of the reporting period, the value of securities loaned amounted to $50,412,024.
** Management fees charged to Putnam Short Term Investment Fund have been waived by Putnam Management. There were no realized or unrealized gains or losses during the period.
***Common stock classifications are presented at the sector level, which may differ from the fund’s portfolio presentation.
(SEGSF) This security, in part or in entirety, was pledged and segregated with the custodian for collateral on certain derivative contracts at the close of the reporting period. Collateral at period end totaled $2,082,417.
(F) This security is valued by Putnam Management at fair value following procedures approved by the Trustees. Securities are classified as Level 3 for ASC 820 based on the securities' valuation inputs. At the close of the reporting period, fair value pricing was also used for certain foreign securities in the portfolio.
(i) This security was pledged, or purchased with cash that was pledged, to the fund for collateral on certain derivative contracts.
(P) This security was pledged, or purchased with cash that was pledged, to the fund for collateral on certain derivative contracts. The rate quoted in the security description is the annualized 7-day yield of the fund at the close of the reporting period.
(S) This security is on loan, in part or in entirety, at the close of the reporting period.
Unless otherwise noted, the rates quoted in Short-term investments security descriptions represent the weighted average yield to maturity.
DIVERSIFICATION BY COUNTRY⌂
Distribution of investments by country of risk at the close of the reporting period, excluding collateral received, if any (as a percentage of Portfolio Value):
United States 75.9 %
Denmark 8.2
United Kingdom 6.4
France 5.4
Japan 3.2
Canada 0.6
Other 0.3
Total 100.0%
⌂ Methodology differs from that used for purposes of complying with the fund’s policy regarding investments in securities of foreign issuers, as discussed further in the fund’s prospectus.
Security valuation: Portfolio securities and other investments are valued using policies and procedures adopted by the Board of Trustees. The Trustees have formed a Pricing Committee to oversee the implementation of these procedures and have delegated responsibility for valuing the fund’s assets in accordance with these procedures to Putnam Management. Putnam Management has established an internal Valuation Committee that is responsible for making fair value determinations, evaluating the effectiveness of the pricing policies of the fund and reporting to the Pricing Committee.
Investments for which market quotations are readily available are valued at the last reported sales price on their principal exchange, or official closing price for certain markets, and are classified as Level 1 securities under ASC 820. If no sales are reported, as in the case of some securities that are traded OTC, a security is valued at its last reported bid price and is generally categorized as a Level 2 security.
Investments in open-end investment companies (excluding exchange-traded funds), if any, which can be classified as Level 1 or Level 2 securities, are valued based on their net asset value. The net asset value of such investment companies equals the total value of their assets less their liabilities and divided by the number of their outstanding shares.
Market quotations are not considered to be readily available for certain debt obligations (including short-term investments with remaining maturities of 60 days or less) and other investments; such investments are valued on the basis of valuations furnished by an independent pricing service approved by the Trustees or dealers selected by Putnam Management. Such services or dealers determine valuations for normal institutional-size trading units of such securities using methods based on market transactions for comparable securities and various relationships, generally recognized by institutional traders, between securities (which consider such factors as security prices, yields, maturities and ratings). These securities will generally be categorized as Level 2.
Many securities markets and exchanges outside the U.S. close prior to the scheduled close of the New York Stock Exchange and therefore the closing prices for securities in such markets or on such exchanges may not fully reflect events that occur after such close but before the scheduled close of the New York Stock Exchange. Accordingly, on certain days, the fund will fair value certain foreign equity securities taking into account multiple factors including movements in the U.S. securities markets, currency valuations and comparisons to the valuation of American Depository Receipts, exchange-traded funds and futures contracts. The foreign equity securities, which would generally be classified as Level 1 securities, will be transferred to Level 2 of the fair value hierarchy when they are valued at fair value. The number of days on which fair value prices will be used will depend on market activity and it is possible that fair value prices will be used by the fund to a significant extent. At the close of the reporting period, fair value pricing was used for certain foreign securities in the portfolio. Securities quoted in foreign currencies, if any, are translated into U.S. dollars at the current exchange rate.
To the extent a pricing service or dealer is unable to value a security or provides a valuation that Putnam Management does not believe accurately reflects the security's fair value, the security will be valued at fair value by Putnam Management in accordance with policies and procedures approved by the Trustees. Certain investments, including certain restricted and illiquid securities and derivatives, are also valued at fair value following procedures approved by the Trustees. These valuations consider such factors as significant market or specific security events such as interest rate or credit quality changes, various relationships with other securities, discount rates, U.S. Treasury, U.S. swap and credit yields, index levels, convexity exposures, recovery rates, sales and other multiples and resale restrictions. These securities are classified as Level 2 or as Level 3 depending on the priority of the significant inputs.
To assess the continuing appropriateness of fair valuations, the Valuation Committee reviews and affirms the reasonableness of such valuations on a regular basis after considering all relevant information that is reasonably available. Such valuations and procedures are reviewed periodically by the Trustees. The fair value of securities is generally determined as the amount that the fund could reasonably expect to realize from an orderly disposition of such securities over a reasonable period of time. By its nature, a fair value price is a good faith estimate of the value of a security in a current sale and does not reflect an actual market price, which may be different by a material amount.
Forward currency contracts: The fund buys and sells forward currency contracts, which are agreements between two parties to buy and sell currencies at a set price on a future date. These contracts were used to hedge foreign exchange risk.
The U.S. dollar value of forward currency contracts is determined using current forward currency exchange rates supplied by a quotation service. The fair value of the contract will fluctuate with changes in currency exchange rates. The contract is marked to market daily and the change in fair value is recorded as an unrealized gain or loss. The fund records a realized gain or loss equal to the difference between the value of the contract at the time it was opened and the value at the time it was closed when the contract matures or by delivery of the currency. The fund could be exposed to risk if the value of the currency changes unfavorably, if the counterparties to the contracts are unable to meet the terms of their contracts or if the fund is unable to enter into a closing position.
For the fund's average contract amount on forward currency contracts, see the appropriate table at the end of these footnotes.
Master agreements: The fund is a party to ISDA (International Swaps and Derivatives Association, Inc.) Master Agreements (Master Agreements) with certain counterparties that govern OTC derivative and foreign exchange contracts entered into from time to time. The Master Agreements may contain provisions regarding, among other things, the parties’ general obligations, representations, agreements, collateral requirements, events of default and early termination. With respect to certain counterparties, in accordance with the terms of the Master Agreements, collateral posted to the fund is held in a segregated account by the fund’s custodian and, with respect to those amounts which can be sold or repledged, is presented in the fund’s portfolio.
Collateral pledged by the fund is segregated by the fund’s custodian and identified in the fund’s portfolio. Collateral can be in the form of cash or debt securities issued by the U.S. Government or related agencies or other securities as agreed to by the fund and the applicable counterparty. Collateral requirements are determined based on the fund’s net position with each counterparty.
Termination events applicable to the fund may occur upon a decline in the fund’s net assets below a specified threshold over a certain period of time. Termination events applicable to counterparties may occur upon a decline in the counterparty’s long-term and short-term credit ratings below a specified level. In each case, upon occurrence, the other party may elect to terminate early and cause settlement of all derivative and foreign exchange contracts outstanding, including the payment of any losses and costs resulting from such early termination, as reasonably determined by the terminating party. Any decision by one or more of the fund’s counterparties to elect early termination could impact the fund’s future derivative activity.
At the close of the reporting period, the fund had a net liability position of $2,601,522 on open derivative contracts subject to the Master Agreements. Collateral posted by the fund at period end for these agreements totaled $2,082,417 and may include amounts related to unsettled agreements.








ASC 820 establishes a three-level hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of the fund's investments. The three levels are defined as follows:
Level 1: Valuations based on quoted prices for identical securities in active markets.
Level 2: Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
Level 3: Valuations based on inputs that are unobservable and significant to the fair value measurement.
The following is a summary of the inputs used to value the fund's net assets as of the close of the reporting period:
  Valuation inputs
Investments in securities: Level 1 Level 2 Level 3
Common stocks*:
Consumer staples $6,493,106 $— $—
Health care 1,138,231,353 302,165,598 —
Total common stocks 1,144,724,459 302,165,598 —
U.S. treasury obligations — 2,472,071 —
Short-term investments 980,000 123,881,940 —
Totals by level $1,145,704,459 $428,519,609 $—
  Valuation inputs
Other financial instruments: Level 1 Level 2 Level 3
Forward currency contracts $— $(74,641) $—
Totals by level $— $(74,641) $—
* Common stock classifications are presented at the sector level, which may differ from the fund's portfolio presentation.
The volume of activity for the reporting period for any derivative type that was held at the close of the period is listed below and was based on an average of the holdings of that derivative at the end of each fiscal quarter in the reporting period:
Forward currency contracts (contract amount) $633,600,000
For additional information regarding the fund please see the fund's most recent annual or semiannual shareholder report filed on the Securities and Exchange Commission's Web site, www.sec.gov, or visit Putnam's Individual Investor Web site at www.putnaminvestments.com